Gvia-M 50mg/1000mg Tablets is primarily indicated in conditions like Atherosclerosis, Myocardial infarction, Myocardial infarction prophylaxis, Peripheral arterial disease, Prophylaxis for NSAID-associated gastric and duodenal ulcers, Stroke, Stroke prophylaxis, Thrombo-embolic complications, and can also be given in adjunctive therapy as an alternative drug of choice in Angina, Unstable angina.
Gvia-M 50mg/1000mg Tablets is contraindicated in conditions like Peptic ulcer,Intracranial hemorrhage, Hypersensitivity.
The severe or irreversible adverse effects of Gvia-M 50mg/1000mg Tablets , which give rise to further complications include Hepatitis, Oedema.The signs and symptoms that are produced after the acute overdosage of Gvia-M 50mg/1000mg Tablets include BLood dyscrasias. The symptomatic adverse reactions produced by Gvia-M 50mg/1000mg Tablets are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Fatigue, Nausea, Diarrhea, Abdominal pain, Rashes, Skin Rashx, Dyspepsia, Depression, Arthralgia, Influenza like syndrome, Chest pain, Gl disturbance, Epistaxis.
Patients should be observed carefully for signs and symptoms of pancreatitis. If pancreatitis is suspected, Sitagliptin should promptly be discontinued and appropriate management should be initiated. A dosage adjustment is recommended in patients with moderate or severe renal insufficiency and in patients with ESRD requiring hemodialysis or peritoneal dialysis. Use caution when used in conjunction with sulfonylureas; risk of hypoglycemia is increased. Monitor blood glucose closely; dosage adjustments of the sulfonylurea may be necessary. Safety and efficacy have not been established in children
There are no reviews yet.